Soy Isoflavones in the Prevention of Menopausal Bone Loss and Menopausal Symptoms

In this 2-year randomized trial, we found that tablets containing 200 mg of isoflavones extracted from soy protein administered once daily were not superior to placebo in preventing bone loss or in reducing bone turnover or menopausal symptoms in women in the first 5 years of menopause

Silvina Levis

2011

Scholarcy highlights

  • Concerns regarding the risk of estrogen replacement have resulted in a significant increase in the use of soy products by menopausal women who, despite the lack of evidence of the efficacy of such products, seek alternatives to menopausal hormone therapy
  • After 2 years, no significant differences were found between the participants receiving soy tablets and those receiving placebo regarding changes in bone mineral density in the spine, the total hip, or the femoral neck
  • The primary objectives of the study were to determine whether daily intake of 200 mg of soy isoflavones in tablet form prevents the rapid bone loss associated with the initial menopausal years, as measured by the bone mineral density of the lumbar spine, the total hip, and the femoral neck compared with placebo
  • All fractures were associated with a traumatic event and were not considered to be osteoporotic fractures. In this 2-year randomized trial, we found that tablets containing 200 mg of isoflavones extracted from soy protein administered once daily were not superior to placebo in preventing bone loss or in reducing bone turnover or menopausal symptoms in women in the first 5 years of menopause
  • A significant difference was observed in dropouts between the treatment groups; this is not an indication that the women taking soy isoflavone tablets were experiencing some type of favorable effect from the intervention because we were unable to objectively document any benefit and a similar
  • With a sample size of 130 in each group, the study has a greater than 80% power to detect a 4.0% or greater difference in BMD of the lumbar spine with the assumption that the control group will lose 4.0% to 5.0% bone mass
  • We found that our population of women in the first 5 years of menopause, on average, had low rates of bone loss, and that 200 mg of soy isoflavone tablets taken once daily does not prevent bone loss or reduce bone turnover or menopausal symptoms
  • The daily administration of tablets containing 200 mg of soy isoflavones for 2 years did not prevent bone loss or menopausal symptoms

Need more features? Save interactive summary cards to your Scholarcy Library.